US Regulatory Reads, February 2018: Funding, Digital Health And Program Alignment
Executive Summary
While the overall FY 2019 Trump administration budget request submitted last month was widely criticized, the high numbers slated for US FDA in the document attracted positive attention in the life-sciences space, and among Medtech Insight readers. Also popular among US regulatory and policy content last month: coverage of a digital-health gathering, program alignment insights and stories on FDA restructuring, federal enforcement and adverse events trends.
You may also be interested in...
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?
Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.